CL2008000796A1 - Uso de 4-(2-(4-metilfenilsulfanil)fenil)piperidina y sales de adicion de acidos de la misma para el tratamiento del adhd, melancolia, depresion o sintomas residuales de la depresion; y dicho compuesto. - Google Patents

Uso de 4-(2-(4-metilfenilsulfanil)fenil)piperidina y sales de adicion de acidos de la misma para el tratamiento del adhd, melancolia, depresion o sintomas residuales de la depresion; y dicho compuesto.

Info

Publication number
CL2008000796A1
CL2008000796A1 CL200800796A CL2008000796A CL2008000796A1 CL 2008000796 A1 CL2008000796 A1 CL 2008000796A1 CL 200800796 A CL200800796 A CL 200800796A CL 2008000796 A CL2008000796 A CL 2008000796A CL 2008000796 A1 CL2008000796 A1 CL 2008000796A1
Authority
CL
Chile
Prior art keywords
depression
melancolia
adhd
piperidine
phenyl
Prior art date
Application number
CL200800796A
Other languages
English (en)
Inventor
Tine Bryan Stensbol
Silke. Miller
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2007/050076 external-priority patent/WO2007144006A1/en
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CL2008000796A1 publication Critical patent/CL2008000796A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CL200800796A 2007-03-20 2008-03-19 Uso de 4-(2-(4-metilfenilsulfanil)fenil)piperidina y sales de adicion de acidos de la misma para el tratamiento del adhd, melancolia, depresion o sintomas residuales de la depresion; y dicho compuesto. CL2008000796A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200700423 2007-03-20
PCT/DK2007/050076 WO2007144006A1 (en) 2006-06-16 2007-06-15 Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain

Publications (1)

Publication Number Publication Date
CL2008000796A1 true CL2008000796A1 (es) 2008-09-26

Family

ID=39575680

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800796A CL2008000796A1 (es) 2007-03-20 2008-03-19 Uso de 4-(2-(4-metilfenilsulfanil)fenil)piperidina y sales de adicion de acidos de la misma para el tratamiento del adhd, melancolia, depresion o sintomas residuales de la depresion; y dicho compuesto.

Country Status (28)

Country Link
US (2) US20100144788A1 (es)
EP (2) EP2139479B1 (es)
JP (1) JP5388867B2 (es)
KR (1) KR20090125775A (es)
CN (2) CN101646438B (es)
AR (1) AR065798A1 (es)
AU (1) AU2008228639B2 (es)
BR (1) BRPI0808831A2 (es)
CA (1) CA2684556C (es)
CL (1) CL2008000796A1 (es)
CO (1) CO6220957A2 (es)
CY (2) CY1113965T1 (es)
DK (2) DK2139479T3 (es)
EA (1) EA017407B1 (es)
ES (2) ES2399305T3 (es)
HK (1) HK1142007A1 (es)
HR (1) HRP20130049T1 (es)
IL (1) IL200954A (es)
MX (1) MX2009009934A (es)
MY (1) MY163537A (es)
NZ (1) NZ579723A (es)
PL (2) PL2139479T3 (es)
PT (2) PT2139479E (es)
RS (2) RS52676B (es)
SI (1) SI2139479T1 (es)
TW (1) TWI432194B (es)
UA (2) UA99611C2 (es)
WO (1) WO2008113360A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA016054B1 (ru) * 2006-06-16 2012-01-30 Х. Лундбекк А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил] пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
JP5764327B2 (ja) * 2007-06-15 2015-08-19 ハー・ルンドベック・アクチエゼルスカベット 過敏性腸症候群（ｉｂｓ）を処置するための４−［２−（４−メチルフェニルスルファニル）フェニル］ピペリジン
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
US8920840B2 (en) * 2010-04-30 2014-12-30 Takeda Pharmaceutical Company Limited Enteric tablet
US9311462B1 (en) 2011-03-04 2016-04-12 Zynga Inc. Cross platform social networking authentication system
US8332488B1 (en) 2011-03-04 2012-12-11 Zynga Inc. Multi-level cache with synch
US10135776B1 (en) 2011-03-31 2018-11-20 Zynga Inc. Cross platform social networking messaging system
US8347322B1 (en) 2011-03-31 2013-01-01 Zynga Inc. Social network application programming interface
US8522137B1 (en) 2011-06-30 2013-08-27 Zynga Inc. Systems, methods, and machine readable media for social network application development using a custom markup language
US9820984B1 (en) 2016-07-01 2017-11-21 H. Lundbeck A/S Dosing regimens for fast onset of antidepressant effect

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139592A (en) * 1998-05-22 2005-08-31 Lilly Co Eli Pharmaceutical composition containing an atypical antipsychotic and a serotonin reuptake inhibitor for combination therapy of refractory depression
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
DE602004016316D1 (de) * 2003-04-04 2008-10-16 Lundbeck & Co As H 4-(2-phenylsulfanyl-phenyl)-piperidin-derivate als serotonin-wiederaufnahme-hemmer
MXPA05010627A (es) * 2003-04-04 2005-12-12 Lundbeck & Co As H Derivados de 4-(2-feniloxifenil)-piperidina o 1,2,3,6-tetrahidropiridina como inhibidores de la recaptacion de serotonina.
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
DE102006028034A1 (de) * 2006-06-14 2007-12-20 Leifheit Ag Bürste und Kehrgerät mit Bürste
EA016054B1 (ru) * 2006-06-16 2012-01-30 Х. Лундбекк А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил] пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли
TWI405588B (zh) 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter

Also Published As

Publication number Publication date
PL2167085T3 (pl) 2014-08-29
ES2445400T3 (es) 2014-03-03
CN101674830A (zh) 2010-03-17
HK1142007A1 (en) 2010-11-26
PT2139479E (pt) 2013-02-20
BRPI0808831A2 (pt) 2014-08-26
CA2684556A1 (en) 2008-09-25
AR065798A1 (es) 2009-07-01
UA97660C2 (ru) 2012-03-12
DK2139479T3 (da) 2013-02-11
US20100137366A1 (en) 2010-06-03
US8507526B2 (en) 2013-08-13
NZ579723A (en) 2011-07-29
KR20090125775A (ko) 2009-12-07
US20100144788A1 (en) 2010-06-10
MY163537A (en) 2017-09-15
CA2684556C (en) 2013-01-08
EP2167085A1 (en) 2010-03-31
EA200970871A1 (ru) 2010-04-30
EA017407B1 (ru) 2012-12-28
PL2139479T3 (pl) 2013-05-31
TW200848032A (en) 2008-12-16
ES2399305T3 (es) 2013-03-27
CN101646438B (zh) 2012-04-11
CN101646438A (zh) 2010-02-10
JP5388867B2 (ja) 2014-01-15
SI2139479T1 (sl) 2013-04-30
EP2139479A2 (en) 2010-01-06
IL200954A (en) 2014-12-31
RS52676B (en) 2013-06-28
MX2009009934A (es) 2009-09-24
EP2139479B1 (en) 2012-12-12
TWI432194B (zh) 2014-04-01
DK2167085T3 (da) 2014-02-03
CY1113965T1 (el) 2016-07-27
CO6220957A2 (es) 2010-11-19
WO2008113360A3 (en) 2008-11-13
CN101674830B (zh) 2012-05-09
HRP20130049T1 (hr) 2013-02-28
AU2008228639A1 (en) 2008-09-25
WO2008113360A2 (en) 2008-09-25
UA99611C2 (ru) 2012-09-10
AU2008228639B2 (en) 2012-12-13
JP2010521502A (ja) 2010-06-24
IL200954A0 (en) 2010-05-17
CY1114774T1 (el) 2016-12-14
RS53138B (en) 2014-06-30
EP2167085B1 (en) 2013-12-25
PT2167085E (pt) 2014-02-17

Similar Documents

Publication Publication Date Title
CL2008000796A1 (es) Uso de 4-(2-(4-metilfenilsulfanil)fenil)piperidina y sales de adicion de acidos de la misma para el tratamiento del adhd, melancolia, depresion o sintomas residuales de la depresion; y dicho compuesto.
CL2008000795A1 (es) Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil)piperazina para el tratamiento del dolor o de los sintomas residuales de la depresion; y dicho compuesto.
RS54457B1 (en) CRYSTAL (R) - (E) -2- (4- (2- (5- (1- (3,5-Dichloropyridin-4-yl) ethoxy) -1H-indazol-3-yl) vinyl) -1H- PIRAZOL-1-IL) ETHANOL AND ITS USE AS FGFR INHIBITOR
SMT201600057B (it) 3,5-diammino-6-cloro-n-(n-(4-(4-(2-(esil(2,3,4,5,6-pentaidrossiesil)ammino)etossi)fenil)butil)- carbammimidoil)pirazina-2-carbossammide
CL2015000291A1 (es) Formas solidas que comprenden sales de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona.
CO6400224A2 (es) Purificación de 1-[2-(2-4-dimetilfenilsulfanil)fenil]piperazina
CY1112483T1 (el) Αγωνιστες gpcr πιπεριδινης
ECSP11011469A (es) Sales de disacarina, ácido difumárico, ácido di-1-hidroxi-2-naftoico y ácido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato de 4-(dimetilamino)butilo
PE20150998A1 (es) Inhibidores de histona demetilasas
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
DK1954668T3 (da) Homo- og heterocykliske forbindelser, der er egnede som CETP-inhibitorer
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CL2009000914A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-n-sustituidas-sulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica.
CL2009000915A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-bencenosulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica (copd).
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CY1113178T1 (el) Σταθεροποιημενες αμορφες μορφες της μεσυλικης ιματινιβης
CL2008000110A1 (es) Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.
CO6361993A2 (es) Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina
ECSP10010150A (es) Forma cristalina 1 de 2-(r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida
BRPI0915130A2 (pt) derivado de ácido 7h-indolo{2,1-a]{2]-benzapina-10-carboxílico para o tratamento de hepatite c
DE602006020998D1 (de) Monolysinsalze von azolverbindungen
DE502008002979D1 (de) Arylsulfonamide mit analgetischer wirkung
CL2008000949A1 (es) Compuestos derivados de 2,3-benzodiazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos psicoticos.